Study data support using long-acting cabotegravir or long-acting rilpivirine, given every 4 weeks or 8 weeks, per the adult dosing regimens, in virologically suppressed adolescents aged 12 years and older and weighing at least 35 kg ..read more

High acceptability and tolerability of long-acting cabotegravir or rilpivirine injections suggests that these are likely to be favoured treatment options for some adolescents living with HIV ..read more

It is with great interest that we read Denton Callander and colleagues’ Article on the population-level effectiveness of HIV treatment-as-prevention on HIV incidence among gay, bisexual, and other men who have sex with men (GBM) in Australia.1 The authors conclude that, between 2010 and 2019, a 1% increase in the population prevalence of viral suppression was associated with a 5% decrease in HIV incidence among GBM. Particularly noteworthy were the results from the analysis stratified into the period before (2010–16) and after (2016–19) pre-exposure prophylaxis (PrEP) became available ..read more

We welcome the engagement with our study of HIV treatment-as-prevention by Eline S Wijstma and colleagues, and thank them for raising some interesting questions about the results ..read more

In May, 2010, results of the multicountry iPrEx study were released: daily oral co-formulated emtricitabine and tenofovir disoproxil fumarate effectively prevented HIV infection among men who have sex with men (MSM) and transgender women.1 The new intervention, pre-exposure prophylaxis (PrEP), was approved by the US Food and Drug Administration in 2012, and a broad global scale-up was anticipated. In Peru, where more than half of all iPrEx participants were enrolled, PrEP was urgently needed, and in 2016 its use was approved by the Ministry of Health; however, access was limited to demonstrati ..read more

Adolescents with HIV have worse health outcomes along each step of the HIV care cascade worldwide compared with adults.1 Considerable socioeconomic, behavioural, and developmental differences between adolescents and adults contribute to this health inequity.2 Adolescents with HIV face multiple challenges in initiating and adhering to oral HIV treatment, including being able to independently access confidential health care, dual HIV and sexual and reproductive health stigma, poverty, violence, limited health literacy, risk-taking behaviour, mental health distress, and substance abuse ..read more

This February, Zambia took an important step forward in the fight against HIV and became the first African country to offer cabotegravir long-acting injectable (CAB-LA) for HIV prevention outside of a study setting. The long-expected roll-out of CAB-LA for pre-exposure prophylaxis (PrEP) comes thanks to a partnership between Zambia's Ministry of Health and the United States Agency for International Development (USAID). It kickstarted with an initial drug donation from USAID that will provide HIV prevention to 2000 Zambians for 12 months ..read more

BAIS V is the first population-based survey worldwide to report the achievement of the UNAIDS 95-95-95 goals, both overall and among women. Strategies to reach undiagnosed men and young people, including young women, are needed ..read more

When proposed a decade ago, the UNAIDS 90-90-90 targets were described as aggressive, ambitious, and daunting.1 Nevertheless, these milestones have had a profound effect on HIV responses, galvanizing efforts globally. In The Lancet HIV, Madisa Mine and colleagues2 provide empirical evidence that Botswana, which has one of the highest global prevalences of HIV (one in five adults are living with HIV), has achieved the 95-95-95 targets in 2021, 4 years ahead of the 2025 deadline. The Fifth Botswana AIDS Impact Survey (BAIS V) showed that 92% of people living with HIV were virally suppressed, whi ..read more

The geographical distribution of malaria and HIV infections widely overlap in sub-Saharan Africa, constituting a complex global health challenge. The interplay between both infections raises concerns about potential immunological, clinical, and therapeutic interactions. Both diseases have been reported to exacerbate the transmission of the other, including the possible vertical transmission of HIV in pregnant individuals with malaria. Co-infection also increases the risk of adverse outcomes such as severe malaria and death ..read more